论文部分内容阅读
背景与目的肺癌是当今世界上最常见的恶性肿瘤之一,迄今缺乏临床诊断可用的分子标志物。本实验应用SELDI技术寻找肺癌新的血清标志物。方法对227例血清样品(包括146例肺癌、13例肺炎、28例结核性胸膜炎和40例正常人血清样品)进行蛋白质谱检测。对候选蛋白进行质谱鉴定,并结合免疫共沉淀和ELISA技术筛选出肺癌新的候选标志物。结果通过Biomarker WizardTM软件分析显示13.78kDa、13.90kDa和14.07kDa的蛋白峰在肺癌病人血清样品中明显低于对照组。通过1-D胶分离,质谱鉴定和免疫沉淀分析显示这3个差异蛋白峰为野生型甲状腺运载蛋白(nativeTTR)和它的两个变体(cysTTR and glutTTR)。ELISA和SELDI技术分析上述血清样品均发现TTRs在肺癌血清中的表达下调。结论采用SELDI技术首次筛选并鉴定出TTRs,表明其可能作为肺癌诊断的候选血清标志物。
BACKGROUND & OBJECTIVE Lung cancer is one of the most common malignant tumors in the world. So far, there are no molecular markers available for clinical diagnosis. SELDI technology in this experiment to find new serum markers of lung cancer. Methods 227 serum samples (including 146 cases of lung cancer, 13 cases of pneumonia, 28 cases of tuberculous pleurisy and 40 cases of normal human serum samples) were detected by protein profile. Candidate proteins were identified by mass spectrometry, and combined with co-immunoprecipitation and ELISA technology screening of lung cancer candidate markers. Results Analysis by Biomarker WizardTM software showed that the protein peaks of 13.78 kDa, 13.90 kDa and 14.07 kDa were significantly lower in the serum samples of lung cancer patients than in the control group. Mass spectrometry and immunoprecipitation analysis revealed that these three differential protein peaks were wild-type thyrotrophic (nativeTTR) and its two variants (cysTTR and glutTTR) by 1-D gel separation. ELISA and SELDI technology analysis of the above serum samples were found TTRs downregulated in lung cancer serum. Conclusion SELDI technique was used to screen and identify TTRs for the first time, which indicates that it may serve as a candidate serum marker for diagnosis of lung cancer.